Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
Shilpika BajpaiMichael J MarinoMatthew A RankAngela M DonaldsonErin K O'BrienDevyani LalPublished in: International forum of allergy & rhinology (2021)
Anti-IL-5 agents were associated with improved CT and SNOT-22 scores in the overall CRS group and in CRSwNP subgroup; CRSsNP patients showed improved CT scores only. Omalizumab improved CT but not SNOT-22 scores. ESS was performed in 22% of patients after initiating biologics. These real-world results may influence future trial designs and clinical applications of biologics for CRS. ©2021 ARSAAOA, LLC.
Keyphrases
- end stage renal disease
- newly diagnosed
- computed tomography
- ejection fraction
- image quality
- prognostic factors
- clinical trial
- contrast enhanced
- chronic obstructive pulmonary disease
- dual energy
- positron emission tomography
- magnetic resonance
- randomized controlled trial
- patient reported outcomes
- study protocol
- cystic fibrosis
- chronic rhinosinusitis
- mesenchymal stem cells
- bone marrow
- patient reported
- phase ii
- pet ct
- double blind